PRI's Focus on Health Care
View this email in your browser ([link removed])
Coronavirus lockdown benefits remain dubious as costs continue to mount
Featured on Fox News | Sally C. Pipes
September 8, 2020
The damage wrought by the draconian response to the pandemic doesn’t end there. The lockdowns have exerted a potentially life-threatening toll on the mental health of many Americans. A CDC report from last month found that one-quarter of adults ages 18 to 24 contemplated suicide in the previous month.
Read more. . . ([link removed])
Pharmaceutical Companies Ruin Prospects for COVID-19 Vaccine “October Surprise”. That’s a Good Thing.
Featured in the Chicago Tribune and Real Clear Science | Henry Miller, M.S., M.D.
September 5, 2020
Well, the companies producing the leading coronavirus vaccine candidates have just effectively ruined the prospects for a pre-election “October Surprise” announcement of a vaccine approval. In an extraordinary move, several drug companies that are developing COVID-19 vaccines, including Johnson & Johnson, Pfizer, Moderna and Sanofi, are about to issue a statement pledging that they won’t seek government approval until their products have been proven to be safe and effective, and to adhere to the highest standards in clinical trials and manufacturing.
Read more. . . ([link removed])
COVID-19 Vaccines Must Be Fully Vetted For Safety And Efficacy Before Release
Issues & Insights | Henry Miller, M.S., M.D.
September 5, 2020
It was hardly a secret that there would be intense pressure on the FDA from a White House desperate for good news to provide an “October Surprise” in the form of a vaccine approval before the Nov. 3 election, even if that approval was premature. When I wrote about this subject for Issues & Insights a month ago, I described the wall that the head of the FDA, Dr. Stephen Hahn, and his colleagues had constructed in order to resist that pressure. Well, watch out for falling debris, because the wall is crumbling.
Read more. . . ([link removed])
[link removed]
Watch the Latest "Escape the Drug Pricing Maze Video" ([link removed])
Making Biosimilars & Gene Therapies Affordable & Accessible: 3 Keys to Reform Drug Pricing System
As they approach the end of the Drug Pricing Maze, the Professor and Pete explore reforms to fix a broken system and encourage the use of cheaper biosimilars that can help patients and the health care system save big. They also learn what can be done to make very expensive gene therapies that provide a lot of value for patients more affordable and accessible.
============================================================
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])
Copyright © 2020 *Pacific Research Institute*, All rights reserved.
You are receiving this email because you opted in via our website.
Our mailing address is:
101 Montgomery Street, Suite 1300, San Francisco, CA 94104
Want to change how you receive these emails?
You can ** update your preferences ([link removed])
or ** unsubscribe from this list ([link removed])
.